Abstract
To describe the occurrence of immediate transfusion reactions received by the Risk Management Department of Hospital São Paulo. Cross-sectional and retrospective study which analyzed the notification sheets of transfusion reactions that occurred between May 2002 and December 2016 and were included in the Hemovigilance National System. One thousand five hundred and forty-eight transfusion reaction notification sheets were analyzed, all of which concerned immediate reactions associated with packed red blood cells (72.5%). The most frequently reported reaction was febrile non-hemolytic transfusion reaction, and among severe and moderate cases, allergic reaction was the most common. The most frequently reported signs and symptoms were hyperthermia, sudoresis, chills, and skin lesions. No differences were observed regarding gender and age, and 90.7% of reactions occurred in patients with Rh+ factor. This study allowed for a better assessment and understanding of transfusion reactions, which will help to improve the quality of blood circulation and provide greater safety of patients undergoing transfusion therapy.
Highlights
Blood transfusion is a therapeutic method that is globally accepted and that has been proven effective[1]
Between May 2002 and December 2016, Hospital São Paulo (HSP) reported a total of 1,548 immediate transfusion reactions to ANVISA, which corresponded to 99.3% of the total throughout the period
When we compare this to the findings of this study, we see that we reported 4.65% of all cases received by NOTIVISA (Sistema de Notificação em Vigilância Sanitária) from all institutions of the Sentinel Network between 2002 and 2009(5,8)
Summary
Blood transfusion is a therapeutic method that is globally accepted and that has been proven effective[1]. It involves both benefits and risks, even when it is suitable and, despite its indication, proper administration is necessary because reactions may occur. In the United Kingdom, the hemovigilance system called SHOT (Serious Hazards of Transfusions), which aims to minimize transfusion errors, has reported a significant number of undesirable events related to transfusion and to the use of hemocomponents[3]. Brazil began to discuss hemovigilance in 2000(5), and in 2001 the Brazilian Health Regulatory Agency (ANVISA, as per its acronym in Portuguese), in fulfillment of its mission to promote health and protect people from the risks associated with the use of the products and technologies of health services, suggested the creation of the Brazilian Network of Sentinel Hospitals which, among other purposes, would help to integrate the Hemovigilance National System (SNH – Sistema Nacional de Hemovigilância)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
